PRRT2 and stage 5 chronic kidney disease: In line with beneficial effects of higher αKlotho availability, PKC activity is a driver of kidney disease, in particular of diabetic nephropathy, which is among the leading causes for declining kidney function ultimately resulting in end-stage renal disease [48].